Medical Doctor Program year 2022 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Michael Bennett

Ophthalmology Honolulu, HI Medical Doctor

NPI 1043274111 CMS profile 228237

1620 Ala Moana Blvd, Suite 500, Honolulu, HI 96815

Open in the dashboard

General payments

$107,739

23 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$219,256

6 holdings reported · through program year 2022

Research they led as principal investigator

$82,082 paid to institutions, not to them · program years 2021–2022

Through program year 2022, Michael Bennett of Honolulu, HI is reported in the CMS Open Payments database as having received $107,739 across 23 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $82,082 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $219,256 across 6 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $4,696 4
2021 General $2,928 2
2020 General $52,704 4
2019 General $47,411 13
2024 Ownership $59,628 1
2023 Ownership $59,628 1
2022 Ownership $25,000 1
2021 Ownership $25,000 1
2020 Ownership $25,000 1
2019 Ownership $25,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Bennett
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Michael Bennett were reported at $0. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Michael Bennett Ophthalmology median Middle half National median
2019 $47,411 $258 $104–$655 $163
2020 $52,704 $126 $45–$321 $114
2021 $2,928 $205 $76–$534 $132
2022 $4,696 $266 $100–$678 $149
2023 $0 $308 $117–$745 $160
2024 $0 $340 $127–$846 $164
2025 $0 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Bausch & Lomb, a division of Bausch Health US, LLC $96,155 4 payments
  2. US Retina LLC $10,923 6 payments
  3. Lensar, Inc. $376 4 payments
  4. Allergan Inc. $198 5 payments
  5. Novartis Pharmaceuticals Corporation $32 1 payment
  6. Carl Zeiss Meditec, Inc. $19 1 payment
  7. Johnson & Johnson Surgical Vision, Inc. $19 1 payment
  8. Genentech USA, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Gift $96,045 3 payments
  2. Current or prospective ownership or investment interest $10,923 6 payments
  3. Food and Beverage $771 14 payments
Products named General payments · program years 2019–2022
  1. STELLARIS PC $96,030 3 payments
  2. LENSAR LASER SYSTEM $376 4 payments
  3. LUMIGAN $116 2 payments
  4. COMBIGAN $116 2 payments
  5. DURYSTA $59 2 payments
  6. BOTOX $23 1 payment
  7. VisuMax $19 1 payment
  8. Tecnis 1-piece IOL $19 1 payment
  9. VABYSMO $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

11

Median for Ophthalmology: 891

Drug cost

$245

Median for Ophthalmology: $68,233

Branded share of claims

0%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Latanoprost Generic 11 $245

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Records

23 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Hawaii

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record